ReviewJournal of clinical medicine2026
Rethinking Left Ventricular Noncompaction and Excessive Left Ventricular Trabeculation: Development, Genetics, and a Proposed Conceptual Framework.
Review in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Left ventricular noncompaction (LVNC) has long been treated as a distinct cardiomyopathy defined by excessive left ventricular trabeculation. Human developmental studies no longer support the classical arrest-of-compaction hypothesis and instead favor differential growth of the trabecular and compact layers. Excessive trabeculation is also observed in inherited and developmental cardiomyopathies, as a change accompanying other cardiac disease, in asymptomatic individuals, and reversibly in pregnancy and in athletes. Morphology alone is therefore insufficient to define a disease entity. This narrative, conceptual review re-examines ventricular wall formation, the mechanisms producing excessive trabeculation, genetic heterogeneity, and clinical phenotypes and shows that no single axis organizes LVNC unequivocally. Integrating these elements, excessive trabeculation is organized into three clinical pathophysiologic contexts: primary cardiomyopathy with hypertrabeculation, in which overt cardiomyopathy is not sufficiently explained by another underlying disease or by pathological hemodynamic loading; disease-associated hypertrabeculation; and hypertrabeculation without overt cardiomyopathy. The purpose of this organization is to isolate a candidate disease entity that can be tested, using the attribution step by which current definitions of hypertrophic and dilated cardiomyopathy are themselves constructed. The framework is built on three axes: category, descriptive phenotypic group, and risk modifiers. It is hypothesis-generating; operationalization, interobserver reproducibility, prospective outcomes and external validation remain to be realized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.